Literature DB >> 18849077

Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells.

Kristina E Halcomb1, Sandirai Musuka, Toni Gutierrez, Heather L Wright, Anne B Satterthwaite.   

Abstract

The autoimmune disease systemic lupus erythematosus (SLE) is characterized by loss of tolerance to nuclear antigens such as chromatin, DNA, and RNA. This focused autoreactivity is thought to arise from the ability of DNA or RNA specific B cells to receive dual signals from the BCR and TLR9 or TLR7, respectively. The Tec kinase Btk is necessary for the production of anti-DNA antibodies in several murine models of SLE. To assess the role of Btk in the fate of DNA reactive B cells, we generated Btk-/- mice carrying the 56R anti-DNA Ig transgene on the C57BL/6 background. dsDNA specific B cells were present in 56R.Btk-/- mice, although they were not preferentially localized to the marginal zone. These cells were able to proliferate in response to large CpG DNA containing fragments that require BCR-induced internalization to access TLR9. However, anti-DNA antibodies were not observed in the serum of 56R.Btk-/- mice. A transgene expressing a low level of Btk in B cells (Btk(lo)) restored anti-DNA IgM in these mice. This correlated with partial rescue of proliferative response to BCR engagement and TLR9-induced IL-10 secretion in Btk(lo) B cells. anti-DNA IgG was not observed in 56R.Btk(lo) mice, however. This was likely due, at least in part, to a role for Btk in controlling the expression of T-bet and AID in cells stimulated with CpG DNA. Thus, Btk is required for the initial loss of tolerance to DNA and the subsequent production of pathogenic autoantibodies once tolerance is breached.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849077      PMCID: PMC2893544          DOI: 10.1016/j.molimm.2008.08.278

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  51 in total

1.  Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk.

Authors:  F Martin; J F Kearney
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

2.  The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21.

Authors:  A Cariappa; M Tang; C Parng; E Nebelitskiy; M Carroll; K Georgopoulos; S Pillai
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

3.  T-bet regulates IgG class switching and pathogenic autoantibody production.

Authors:  Stanford L Peng; Susanne J Szabo; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 4.  The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.

Authors:  A B Satterthwaite; O N Witte
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

5.  Editors and editing of anti-DNA receptors.

Authors:  H Li; Y Jiang; E L Prak; M Radic; M Weigert
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

6.  CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.

Authors:  P Lenert; L Stunz; A K YI; A M Krieg; R F Ashman
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-08

7.  Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.

Authors:  M Muramatsu; K Kinoshita; S Fagarasan; S Yamada; Y Shinkai; T Honjo
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

8.  Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.

Authors:  Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein
Journal:  Nature       Date:  2002-04-11       Impact factor: 49.962

9.  Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells.

Authors:  Koon-Guan Lee; Shengli Xu; Ee-Tsin Wong; Vinay Tergaonkar; Kong-Peng Lam
Journal:  J Biol Chem       Date:  2008-02-13       Impact factor: 5.157

10.  Autoreactive B cells in the marginal zone that express dual receptors.

Authors:  Yijin Li; Hui Li; Martin Weigert
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  24 in total

1.  Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

Authors:  Hugues de Lavallade; Ahmad Khoder; Melanie Hart; Anushruti Sarvaria; Takuya Sekine; Abdullah Alsuliman; Stephan Mielke; Alexandra Bazeos; Kate Stringaris; Sara Ali; Dragana Milojkovic; Letizia Foroni; Aristeidis Chaidos; Nichola Cooper; Ian Gabriel; Jane Apperley; Sarah Belsey; Robert J Flanagan; John Goldman; Elizabeth J Shpall; Peter Kelleher; David Marin; Katayoun Rezvani
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

2.  The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells.

Authors:  Kerstin Nündel; Patricia Busto; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Leukoc Biol       Date:  2013-06-26       Impact factor: 4.962

3.  Bruton's Tyrosine Kinase Synergizes with Notch2 To Govern Marginal Zone B Cells in Nonobese Diabetic Mice.

Authors:  James B Case; Rachel H Bonami; Lindsay E Nyhoff; Hannah E Steinberg; Allison M Sullivan; Peggy L Kendall
Journal:  J Immunol       Date:  2015-06-01       Impact factor: 5.422

Review 4.  The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.

Authors:  Wen-Hai Shao; Philip L Cohen
Journal:  Expert Rev Clin Immunol       Date:  2014-03-29       Impact factor: 4.473

5.  Reply.

Authors:  Lindsay E Nyhoff; Leslie J Crofford; Peggy L Kendall
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

6.  SLAP deficiency decreases dsDNA autoantibody production.

Authors:  Lisa K Peterson; Luke F Pennington; Laura A Shaw; Meredith Brown; Eric C Treacy; Samantha F Friend; Øyvind Hatlevik; Kira Rubtsova; Anatoly V Rubtsov; Leonard L Dragone
Journal:  Clin Immunol       Date:  2013-12-31       Impact factor: 3.969

Review 7.  The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

Authors:  Leslie J Crofford; Lindsay E Nyhoff; Jonathan H Sheehan; Peggy L Kendall
Journal:  Expert Rev Clin Immunol       Date:  2016-03-04       Impact factor: 4.473

Review 8.  Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.

Authors:  Michael Y Choi; Thomas J Kipps
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

9.  Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.

Authors:  Lindsay E Nyhoff; Bridgette L Barron; Elizabeth M Johnson; Rachel H Bonami; Damian Maseda; Benjamin A Fensterheim; Wei Han; Timothy S Blackwell; Leslie J Crofford; Peggy L Kendall
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

10.  Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.

Authors:  Lindsay E Nyhoff; Emily S Clark; Bridgette L Barron; Rachel H Bonami; Wasif N Khan; Peggy L Kendall
Journal:  J Immunol       Date:  2018-02-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.